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Key Points
Question
Do 1 or more doses of levocarnitine reduce organ failure in septic shock at 48 hours, and, if so, what is the
likelihood of success in a phase 3 trial?
Findings
In an adaptive randomized, blinded clinical trial of 250 adults, the most efficacious dose of levocarnitine (18
g) demonstrated a posterior probability of efficacy of 0.78, which did not reach the a priori threshold of
0.90.
Meaning
levocarnitine did not meaningfully reduce organ failure at 48 hours in patients with septic shock.
Abstract
Importance
Sepsis induces profound metabolic derangements, while exogenous levocarnitine mitigates metabolic
dysfunction by enhancing glucose and lactate oxidation and increasing fatty acid shuttling. Previous trials in
sepsis suggest beneficial effects of levocarnitine on patient-centered outcomes.
Objectives
To test the hypothesis that levocarnitine reduces cumulative organ failure in patients with septic shock at 48
hours and, if present, to estimate the probability that the most efficacious dose will decrease 28-day
mortality in a pivotal phase 3 clinical trial.
Design, Setting, and Participants
Multicenter adaptive, randomized, blinded, dose-finding, phase 2 clinical trial (Rapid Administration of
Carnitine in Sepsis [RACE]). The setting was 16 urban US medical centers. Participants were patients aged
18 years or older admitted from March 5, 2013, to February 5, 2018, with septic shock and moderate organ
dysfunction.
Interventions
Within 24 hours of identification, patients were assigned to 1 of the following 4 treatments: low (6 g),
medium (12 g), or high (18 g) doses of levocarnitine or an equivalent volume of saline placebo administered
as a 12-hour infusion.
Main Outcomes and Measures
The primary outcome required, first, a greater than 90% posterior probability that the most promising
levocarnitine dose decreases the Sequential Organ Failure Assessment (SOFA) score at 48 hours and,
second (given having met the first condition), at least a 30% predictive probability of success in reducing
28-day mortality in a subsequent traditional superiority trial to test efficacy.
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Results
Of the 250 enrolled participants (mean [SD] age, 61.7 [14.8] years; 56.8% male), 35, 34, and 106 patients
were adaptively randomized to the low, medium, and high levocarnitine doses, respectively, while 75
patients were randomized to placebo. In the intent-to-treat analysis, the fitted mean (SD) changes in the
SOFA score for the low, medium, and high levocarnitine groups were −1.27 (0.49), −1.66 (0.38), and −1.97
(0.32), respectively, vs −1.63 (0.35) in the placebo group. The posterior probability that the 18-g dose is
superior to placebo was 0.78, which did not meet the a priori threshold of 0.90. Mortality at 28 days was
45.9% (34 of 74) in the placebo group compared with 43.3% (45 of 104) for the most promising
levocarnitine dose (18 g). Similar findings were noted in the per-protocol analysis.
Conclusions and Relevance
In this dose-finding, phase 2 adaptive randomized trial, the most efficacious dose of levocarnitine (18 g) did
not meaningfully reduce cumulative organ failure at 48 hours.
Trial Registration
ClinicalTrials.gov Identifier: NCT01665092
Introduction
Sepsis is the leading cause of death in the intensive care unit (ICU),  and mortality approaches 40% at 28
days when shock is present.  Sepsis accounts for $24 billion of annual inpatient hospital costs, making it the
most expensive condition to treat in the United States.  Initial care for sepsis consists of early recognition
and stabilization, combined with adequate source control through the use of broad-spectrum antibiotics
and/or surgical intervention.  Current standard practice to support failing organs is generally limited to fluid
resuscitation, vasopressors, ventilatory support, and renal replacement therapy, as necessary. Despite
significant research investment over the last 5 decades, there remains a lack of specific pharmacologic
therapies targeting the pathophysiology of sepsis. Given the high mortality rate and limited therapeutic
options, development of novel treatments remains a priority.
Metabolic abnormalities in sepsis include hyperglycemia, hyperlactatemia, ketosis, and increased free fatty
acids. Vital organs, such as the heart, change fuel preference in response to a septic insult.  The degree of
metabolic disturbance, characterized by the severity of hyperlactatemia, is strongly predictive of death.
While often considered an indicator of tissue hypoperfusion and anaerobic metabolism, increased lactate
production can result from pyruvate dehydrogenase complex inhibition in sepsis.  levocarnitine may
mitigate some of the metabolic effects of sepsis by simultaneously enhancing fatty acid entry into the
mitochondria, clearing their toxic effects from the cytosol and sequestering intramitochondrial acetate,
leading to a decrease in the inhibitory effect of acetyl–coenzyme A on the pyruvate dehydrogenase
complex.  Preclinical animal models  and 2 small clinical trials of acetyl-l-carnitine  and l-
carnitine  have demonstrated their relative safety and potential efficacy in the reduction of organ
dysfunction and possibly mortality, although the clinical trials were limited by small numbers of participants
and different outcome reporting.
To better understand the potential effects of levocarnitine as a metabolic therapy for sepsis, we conducted a
multicenter adaptive, randomized, blinded, dose-finding, phase 2 clinical trial to compare 3 doses of
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levocarnitine vs placebo. The hypotheses of this study were that 1 or more doses of levocarnitine would
reduce cumulative organ failure compared with placebo and that the most promising dose of levocarnitine
would have at least a 30% probability of demonstrating efficacy in the reduction of 28-day mortality if
carried forward into a pivotal phase 3 clinical trial.
Methods
Study Design
This study was a prospective, randomized, blinded, placebo-controlled clinical trial using Bayesian
response-adaptive randomization and designed to assess the efficacy of levocarnitine to decrease the
Sequential Organ Failure Assessment (SOFA) score (originally the Sepsis-Related Organ Failure
Assessment)  of patients with septic shock. The SOFA score (range, 0-24) is an organ failure scoring
system consisting of 6 physiological systems; a score of 2 or higher is required for the diagnosis of sepsis.
The trial took place from March 5, 2013, to February 5, 2018, in the emergency departments and ICUs of 16
large urban medical centers in the United States. The research protocol was approved by the local
institutional review boards and was performed in accord with Good Clinical Practice guidelines. This study
followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.  The trial
protocol is available in Supplement 1.
Participants
Patients seen at the participating centers during the study period with septic shock and moderate organ
dysfunction were assessed for inclusion. Criteria for inclusion were as follows: (1) patients 18 years or older
with confirmed or presumed infection; (2) the presence of 2 or more systemic inflammatory response
criteria; (3) enrollment within 24 hours of recognition of septic shock with initiation of a standardized sepsis
treatment pathway; (4) the use of high-dose vasopressors (norepinephrine bitartrate >0.05 μg/kg/min,
dopamine hydrochloride >10 μg/kg/min, phenylephrine hydrochloride >0.4 μg/kg/min, epinephrine >0.05
μg/kg/min, or any vasopressin dose) to treat shock for at least 4 hours at the time of enrollment; (5)
cumulative SOFA score of at least 6; (6) and blood lactate level exceeding 18 mg/dl (to convert lactate
level to millimoles per liter, multiply by 0.111). Patients were excluded if they were pregnant or
breastfeeding or had any of the following characteristics: primary diagnosis other than sepsis, an established
do-not-resuscitate status or advance directive restricting aggressive care, any history of seizures, known
inborn error of metabolism, anticipated surgery that would interfere with a 12-hour infusion, active
participation in another interventional trial, cardiopulmonary resuscitation before enrollment, known allergy
to levocarnitine, active warfarin treatment, or severe immunocompromised state (absolute neutrophil count,
<500/μl; to convert neutrophil count to ×10 /l, multiply by 0.001).
Eligible patients were screened 7 days per week using electronic medical record–based reports of admitted
patients receiving both antibiotics and vasopressors and/or pager-based alerts informing study staff
regarding initiation of a sepsis treatment pathway (which composed the screening log), in addition to active
screening of the emergency department tracking board to facilitate earlier identification. Each enrolled
patient or the patient’s legally authorized representative provided written informed consent before
randomization and collection of data.
Treatment Assignment
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After informed consent was obtained, a centralized web-based portal was used to determine treatment
allocation. Patients were randomly assigned to 1 of 3 doses of levocarnitine or saline placebo. During an
initial “burn-in” period of 40 patients, participants were allocated equally among the treatment arms. From
that point on, interim analyses were conducted on every 12 patients. At each interim analysis, the relative
allocation probability of the 3 active treatment arms was adjusted to be proportional to the probability that
each arm would lead to the greatest improvement in the SOFA score. A site-based blocked randomization
approach ensured that approximately one-third of participants were allocated to the control arm throughout
the trial to maintain a sufficient allocation to control and avoid confounding from local changes in usual
care. Predefined stopping rules for both efficacy and futility were determined before trial initiation. The
statistical rationale and methods have been published previously.
Treatment Interventions
The 3 active treatment arms consisted of low (6 g), medium (12 g), and high (18 g) doses of levocarnitine
administered intravenously over a 12-hour period. The control (placebo) consisted of an identical volume of
0.9% saline placebo. After randomization, research pharmacists used a web-based portal to determine
treatment allocation. Pharmacists were the only individuals not masked to treatment, and they had no study-
related contact with the investigators or participants. Pharmacists and staff prepared either levocarnitine or
placebo in identical polypropylene infusion bags with labels that included the study identification number,
patient name, medical record number, and infusion rate. For each dose of levocarnitine, 33% of the total
dose was administered as a 20-ml bolus over 2 to 3 minutes, followed by a fixed-rate continuous infusion
of 1 l over the next 12 hours. The study solution was administered through intravenous (IV) catheters using
US Food and Drug Administration–approved medical equipment (IV tubing, IV pumps, etc). levocarnitine
was provided by leadiant Biosciences (formerly Sigma-Tau Pharmaceuticals) and maintained by pharmacy
staff, with tracking of lot numbers of levocarnitine administered. For safety, clinical physicians could elect
to break study masking, although in no instance did this occur.
Assessments and Outcome Measures
During the study treatment period, the patient’s physiological variables, laboratory results, and medical
treatments were recorded. Sex and race/ethnicity were self-reported. An investigator performed a bedside
assessment and recorded vital signs, vasopressor requirements, ventilator settings, and Glasgow Coma Scale
score at enrollment and 12, 24, and 48 hours later. At enrollment and 48 hours, blood samples were sent to
the clinical laboratory for platelet count, creatinine level, and total bilirubin level to ensure capture of the
SOFA score variables. Nonprotocol (clinical) laboratory results obtained between 0 and 48 hours were
recorded. Patients were followed up until hospital discharge or death and then up to 1 year using the
patient’s electronic medical record and phone calls to the patient or legally authorized representative, cross-
referenced with the Social Security Death Index. Study data were collected and managed using research
electronic data capture (REDCap).
The primary end points were change in the SOFA scores from enrollment to 48 hours, with negative
numbers indicating improvement, and 28-day mortality. In the event of early death before 48 hours, last
value carried forward was used. Secondary outcomes included ICU and hospital length of stay and
percentage of patients undergoing withdrawal of care. Three preplanned, blinded interim safety analyses
were performed: first, after a burn-in phase of 40 patients and then after one-third and two-thirds of
participants were enrolled. The unblinded results were reviewed by an independent data safety monitoring
17
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board with the authority to terminate the study for safety concerns or if the predefined stopping rules for
efficacy or futility were fulfilled.
Statistical Analysis
The trial was considered to have positive findings if (1) the posterior probability of any dose decreasing the
SOFA score at 48 hours more than placebo exceeded 90% and (2) (having met the first condition) there was
at least a 30% predictive probability that the most promising dose of levocarnitine would be successful in
reducing 28-day mortality in a subsequent 2-arm, 2000–total patient phase 3 trial. Based on Monte Carlo
simulation of 30 000 simulated trials enrolling up to 250 patients, the probability of a positive trial assuming
no treatment effect (the type I error rate α) was 4.3%. The power of the trial (β) was dependent on the true
treatment effect. If the true SOFA score effects for the 3 levocarnitine treatment arms were 0, 1, and 2,
corresponding to mortality effects of 0%, 6%, and 12%, respectively, then the power of the trial was 91.1%.
Changes in the SOFA scores between groups were analyzed using a Bayesian approach assuming a normal
dynamic linear model dose response, and posterior probabilities are reported. The normal dynamic linear
model is a Bayesian analogue to a smoothing spline, whose smoothness is determining by a tuning variable.
The tuning variable is given a priori and thus is determined by a combination of the prior and the observed
data. The prior was selected during the design process to provide a smooth fit, while maintaining the main
features of the observed data.
Conditional on a declaration of the SOFA score reduction, predictive probabilities of success in a
subsequent phase 3 trial were calculated using noninformative priors. Except for these primary outcomes,
remaining data were analyzed using frequentist statistics. Categorical data were compared using χ  tests,
while continuous variables were compared with analysis of variance or Wilcoxon rank sum test based on
normality. All non-Bayesian tests were 2-sided, with P < .05 considered significant. All trial design
simulations, interim analyses, and Bayesian statistics were performed using the Fixed and Adaptive Clinical
Trial Simulator Software (FACTS) (Berry Consultants, llC), while frequentist statistics were conducted
using Stata 15.1 (StataCorp).
Results
We screened 2694 individuals and enrolled 250 patients (mean [SD] age, 61.7 [14.8] years; 56.8% male).
The most efficacious dose of levocarnitine (18 g) demonstrated 78% and 77% probabilities of superiority
compared with placebo in the intent-to-treat (ITT) and per-protocol (PP) analyses, respectively. The
CONSORT study flow diagram and reasons for exclusion are shown in Figure 1. Groups were well matched
for baseline demographics, comorbidities, physiological variables, and severity of illness measurements
with the exception of age, which was older in the low- and medium-dose groups, and Acute Physiology and
Chronic Health Evaluation (APACHE) II scores,  which were lowest in the high-dose group and highest in
the medium-dose group despite well-matched SOFA scores (Table 1). Interventions administered did not
differ significantly between groups (Table 2).
One patient in the high-dose group requested withdrawal before initiation of infusion, leaving 249 patients
for the ITT analysis. After the 40-patient burn-in phase of equal allocation across all 4 treatment arms,
45.7% (96 of 210) of patients were preferentially randomized to the high dose while maintaining
approximately one-third (31.0% [65 of 210]) in the placebo arm. In total, 35, 34, and 106 patients were
adaptively randomized to the low, medium, and high levocarnitine doses, respectively, with 75 patients
2
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randomized to placebo. Forty-one patients died before the 48-hour time point and required last SOFA score
carried forward to calculate the primary outcome. Two additional patients withdrew after treatment,
permitting no 28-day mortality assessment, leaving 247 patients for the modified ITT analysis. An
additional 17 patients never began (n = 4) or did not complete (n = 13) the 12-hour infusion. After exclusion
of these patients and withdrawals, 230 patients remained for the PP analysis. Reasons for failing to begin the
infusion included actual or imminent death after consent but before drug infusion (n = 3) and insufficient IV
access to allow study drug infusion (n = 1). Reasons for early cessation of infusion included death before 12
hours (n = 7), family request to stop infusion (n = 2), withdrawal of care or transition to comfort measures
(n = 2), local allergic reaction to infusion (n = 1), and patient request due to development of burning
sensation in the throat (n = 1).
The mean (SD) baseline SOFA score was 11.1 (3.6), and the overall 28-day mortality rate was 46.6% (115
of 247). The raw and fitted change in the SOFA scores and 28-day mortality rates for the ITT and PP
analyses, as well as the probability that each dose is more efficacious than placebo, are listed in Table 3. In
the ITT analysis, the fitted mean (SD) changes in the SOFA score for the low, medium, and high
levocarnitine groups were −1.27 (0.49), −1.66 (0.38), and −1.97 (0.32), respectively, vs −1.63 (0.35) in the
placebo group. The posterior probability that the 18-g dose is superior to placebo was 0.78, which did not
meet the a priori threshold of 0.90. Mortality at 28 days was 45.9% (34 of 74) in the placebo group
compared with 43.3% (45 of 104) for the most promising levocarnitine dose (18 g). The raw and fitted
mortality rates for both the modified ITT and PP analyses are shown in Figure 2. The high (18 g) dose of
levocarnitine demonstrated the most favorable raw (0.35 in ITT) and fitted (0.34 in ITT) decreases in the
SOFA score for the primary outcome at 48 hours in both the ITT and PP analyses. None of these changes
met the a priori threshold for study success. The high dose showed the most efficacious effect on 28-day
mortality, with a modest (3%) decrease in the modified ITT analysis but a more clinically significant effect
(5%-6% decrease) in the PP analyses. The predicted probabilities of success of high-dose carnitine in a
phase 3 pivotal trial with a mortality end point in the ITT and PP analyses were 0.40 and 0.50, respectively.
We observed no significant differences in the median ICU length of stay across the placebo (7 days;
interquartile range [IQR], 3-15 days), low-dose (6 days; IQR, 4-11 days), medium-dose (7 days; IQR, 3-13
days), and high-dose (6 days; IQR, 3-15 days) arms (P = .90). Additional median numbers of hospital days
after ICU discharge did not differ significantly: 8 days (IQR, 1-18 days), 4 days (IQR, 1-13 days), 5 days
(IQR, 1-17 days), and 6 days (IQR, 0-14 days), respectively (P = .48). We observed no difference in the
proportion of patients who had care withdrawn: 0.13, 0.20, 0.12, and 0.07, respectively (P = .15). The
median number of ICU days was 8 days (IQR, 4-20 days) for survivors vs 5 days (IQR, 2-10 days) for
nonsurvivors. The median number of non-ICU hospital days was 16 days (IQR, 9-28 days) among survivors
vs 7 days (IQR 3-14 days) among nonsurvivors.
Discussion
In this adaptive, double-blinded, parallel-group randomized clinical trial, we randomized 250 patients with
septic shock and moderate organ dysfunction to treatment with 1 of 3 doses of levocarnitine or to saline
placebo. The most efficacious dose of levocarnitine (18 g) demonstrated 78% and 77% probabilities of
superiority compared with placebo in the ITT and PP analyses, respectively. For study interpretation,
standard 95% CIs can be calculated using the raw mean (SE) of ±1.96 listed in Table 3. Therefore, the study
did not meet the a priori 90% posterior probability of a reduction in the SOFA score required.
As opposed to the majority of sepsis trials investigating ancillary pharmacologic agents that have focused on
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modulation of inflammation  or coagulation,  this approach to sepsis pharmacotherapy was
innovative in that we attempted to target one of the known metabolic derangements of sepsis. Sepsis-
induced alterations of metabolism are diverse and predictive of outcome.  Most trials in sepsis target
inflammatory or coagulation cascades, while examples of metabolic approaches to the condition are sparse.
Although insulin therapy has been extensively investigated in critically ill patients, including those with
sepsis with mixed results,  most studies have targeted glycemic control. Trials of micronutrients and
feeding regimens, often with the implicit aim of correcting deficiencies, have been investigated, but strong
evidence for specific micronutrient provision beyond early enteral feeding remains lacking.  In this trial,
we sought to supplement all patients with a metabolic nutrient, with the goal of improving organ function
regardless of underlying deficiency. Although our trial did not meet a priori efficacy outcomes, metabolic
manipulation may still represent a viable therapeutic target with alternative metabolically active agents.
We conducted this trial in undifferentiated patients with septic shock and moderate organ dysfunction, but it
has become increasingly apparent that sepsis represents a heterogeneous condition, which may contribute to
the poor historical success rates. Future phenotyping through the use of pharmacometabolomics  may
identify patients amenable to metabolic support and increase the likelihood of trial success. Phenotyping a
cohort of patients enrolled in a smaller, similar trial of levocarnitine demonstrated a clinically occult cohort
who appeared more responsive to treatment and showed disproportionate clinical benefit.  It remains
possible that levocarnitine drug responsiveness may be predictable based on metabolic phenotyping or
assessment of levocarnitine deficiency and provide more precise enrollment criteria for subsequent studies.
Independent of the efficacy of levocarnitine, this trial demonstrates the viability of a Bayesian adaptive
randomization design in acute critical illness trials. The adaptive randomization design preferentially
allocated patients toward the most efficacious high dose and away from the underperforming low and
medium doses. Simultaneously, it maintained allocation to placebo patients to account for temporal trends in
epidemiology and treatment. This approach could increase efficiency of trials by minimizing “wasted”
allocation of participants to ineffective treatment arms. In our trial, this adaptive randomization maximized
the use of limited resources and represents a valid strategy to consider in subsequent trials of critically ill
populations.
We believe it is important to carefully consider the interpretation of the observed study outcome,
specifically the predicted probability of success of a subsequent trial. Our calculation of predictive
probability was conditional on meeting the SOFA score change threshold, which did not occur. We would
naturally view the predictive probability of success for a new phase 3 trial to be low; however, without
meeting this threshold, the reported predictive probabilities should be interpreted skeptically because they
may have overestimated the probability of success in a phase 3 trial compared with a model using
assumptions closer to the observed change in the SOFA scores.
Limitations
This trial has several additional limitations to consider. We chose change in the SOFA scores as a surrogate
outcome based on strong correlations between this measure and 28-day mortality.  Whether change in the
SOFA scores and the timing of reassessment (48 hours in this case) represents the “right” surrogate end
point for nonpivotal sepsis trials remains unclear and is an area for future consideration, although the use of
change in the SOFA score as a surrogate outcome is supported by a recent meta-analysis.  While large for
phase 2 trials in sepsis, we enrolled 250 patients, with only 106 enrolled at the highest levocarnitine dose.
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As such, smaller treatment effects may exist that could have been detected in a larger study, although our
study was adequately powered to detect a change in the SOFA scores of 2, which was considered the
minimal clinically significant change a priori. APACHE II scores were lower in the high-dose arm and may
have contributed to the reduced mortality observed, although from a binary standpoint, this hypothesis does
not significantly affect study interpretation given the negative results. While our study was designed and
begun before release of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-
3),  the SOFA score and lactate level were considered in the enrollment criteria, so our results retain
validity in the context of the updated definition. Due to the inclusion of patients with hospital-acquired
infection, determination of a consistent definition for the time of sepsis onset for calculation of the time to
antibiotic use was not possible, so we were unable to ensure the balancing of this factor between treatment
groups. However, as an unmeasured confounder, this variable should be addressed by the randomization
procedure. The specific effect of levocarnitine on metabolism among patients in sepsis was not evaluated
and remains an area of future investigation.
Conclusions
In this dose-finding, phase 2 adaptive randomized trial, patients with septic shock and moderate organ
dysfunction were treated early in the course of illness with low (6 g), medium (12 g), or high (18 g) doses of
levocarnitine or an equivalent volume of saline placebo administered as a 12-hour infusion. None of the
tested doses of levocarnitine meaningfully reduced cumulative organ failure at 48 hours.
Notes
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Consolidated Standards of Reporting Trials (CONSORT) Study Flow Diagram
CPR indicates cardiopulmonary resuscitation; DNR, do not resuscitate; ITT, intent-to-treat; lAR, legally authorized
representative; mITT, modified intent-to-treat; and PP, per-protocol.
Table 1.
Baseline Demographics and Clinical Characteristics of Patients by Treatment Allocation
Variable Saline
Placebo
(n = 75)
Low-Dose
Levocarnitin, 6 g
(n = 35)
Medium-Dose
Levocarnitine, 12 g
(n = 34)
High-Dose
Levocarnitine, 18 g
(n = 106)
Age, mean (SD), y 60.22
(16.50)
67.51 (12.01) 64.91 (12.56) 59.67 (14.50)
Race, No. (%)
White 47 (62.7) 25 (71.4) 21 (61.8) 55 (51.9)
Black 25 (33.3) 8 (22.9) 8 (23.5) 39 (36.8)
Asian 0 1 (2.9) 1 (2.9) 3 (2.8)
Other 3 (4.0) 1 (2.9) 4 (11.8) 9 (8.5)
Ethnicity, No. (%)
Hispanic 3 (4.0) 0 3 (8.8) 6 (5.7)
Non-Hispanic 72 (96.0) 35 (100) 31 (91.2) 99 (93.4)
Sex, No. (%)
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Male 39 (52.0) 18 (51.4) 21 (61.8) 64 (60.4)
Female 36 (48.0) 17 (48.6) 13 (38.2) 42 (39.6)
Comorbidities, No.
(%)
Diabetes 26 (34.7) 15 (42.9) 7 (20.6) 37 (34.9)
Chronic obstructive
pulmonary disease
16 (21.3) 7 (20.0) 5 (14.7) 20 (18.9)
Congestive heart
failure
14 (18.7) 3 (8.6) 9 (26.5) 21 (19.8)
Cerebrovascular
accident
7 (9.3) 5 (14.3) 2 (5.9) 15 (14.2)
HIV 1 (1.3) 0 0 5 (4.7)
End-stage renal
disease
5 (6.7) 3 (8.6) 3 (8.8) 11 (10.4)
Active cancer 12 (16.0) 8 (22.9) 3 (8.8) 12 (11.3)
Organ transplant 0 1 (2.9) 2 (5.9) 1 (0.9)
I d lli  l 9 (12 0) 5 (14 3) 6 (17 6) 17 (16 0)
     
 
 
     
  
    
 
 
    
  
  
    
     
    
     
    
    
  
  
     
     
Open in a separate window
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation (score range, 0-71, with higher values
indicating greater organ failure); IQR, interquartile range; SOFA, Sequential Organ Failure Assessment (score
range, 0-24, with higher values indicating greater organ failure).
SI conversion factor: To convert lactate level to millimoles per liter, multiply by 0.111.
Table 2.
Clinical Interventions and Administered Therapies by Treatment Allocation
Variable Saline
Placebo
(n = 75)
Low-Dose
Levocarnitine, 6 g
(n = 35)
Medium-Dose
Levocarnitine, 12 g
(n = 34)
High-Dose
Levocarnitine, 18 g
(n = 106)
P
Value
Fluids administered,
mean (SD), l
24 h Before enrollment 3.80 (2.11) 4.02 (2.92) 4.40 (3.08) 3.94 (2.66) .77
6 h After initiation of
hemodynamic
resuscitation
3.39 (6.00) 3.12 (1.86) 2.74 (1.90) 2.52 (1.89) .50
Mechanical ventilation
No. (%) 55 (73.3) 29 (82.9) 23 (67.6) 78 (73.6) .54
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Total time, median
(IQR), h
113.1
(64.0-
252.6)
127.8 (53.7-210.3) 161.5 (46.0-306.7) 98.6 (41.7-191.8) .46
Corticosteroids, No.
(%)
28 (37.3) 14 (40.0) 17 (50.0) 40 (37.7) .64
Hemodialysis, No. (%) 16 (21.3) 4 (11.4) 2 (5.9) 16 (15.1) .18
Abbreviation: IQR, interquartile range.
Table 3.
Raw and Fitted Change in the SOFA Scores (48-Hour SOFA Score Minus Enrollment SOFA
Score) for the Intent-to-Treat and Per-Protocol Analyses
Variable Raw
Mean
(SE)
Raw
Treatment
Effect
Fitted
Mean
(SD)
Fitted
Treatment
Effect
(SD)
Posterior
Probability of
Treatment
Superior to
Placebo
Mortality
at 28 d,
No./Total
No. (%)
Model
Fitted
Rate
(SD)
Predictive
Probability
of Phase 3
Success
Intent-to-Treat Analysis (n = 249)
Saline
placebo
(n = 75)
−1.80
(0.35)
NA −1.63
(0.35)
NA NA 34/74
(45.9)
0.47
(0.05)
NA
low-dose
levocarnitine,
6 g (n = 35)
−0.34
(0.66)
−1.46 −1.27
(0.49)
−0.37
(0.52)
0.24 20/34
(58.8)
0.51
(0.06)
0.10
Medium-dose
levocarnitine,
12 g (n = 34)
−1.68
(0.61)
−0.12 −1.66
(0.38)
0.03 (0.47) 0.54 16/32
(50.0)
0.48
(0.06)
0.22
High-dose
levocarnitine,
18 g (n = 105)
−2.15
(0.37)
0.35 −1.97
(0.32)
0.34 (0.44) 0.78 45/104
(43.3)
0.44
(0.04)
0.40
Per-Protocol Analysis (n = 230)
Saline
placebo
(n = 72)
−1.91
(0.38)
NA −1.78
(0.36)
NA NA 32/71
(45.1)
0.46
(0.05)
NA
low-dose
levocarnitine,
6 g (n = 32)
−0.57
(0.75)
−1.34 −1.53
(0.48)
−0.25
(0.48)
0.32 16/31
(51.6)
0.47
(0.06)
0.17
a
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Medium-dose
levocarnitine,
12 g (n = 31)
−1.94
(0.65)
0.03 −1.87
(0.38)
−0.09
(0.46)
0.59 15/31
(48.4)
0.45
(0.06)
0.28
High-dose
levocarnitine,
18 g (n = 95)
−2.31
(0.40)
0.40 −2.12
(0.33)
0.33 (0.45) 0.77 37/94
(39.4)
0.41
(0.05)
0.50
Abbreviations: NA, not applicable; SOFA, Sequential Organ Failure Assessment (score range, 0-24, with higher
values indicating greater organ failure).
The predictive probability of phase 3 success has been computed with noninformative priors. In the absence of
meeting the required success threshold for the SOFA score change, these predictive probabilities should be
interpreted skeptically. Negative raw mean and positive treatment effects on the SOFA scores reflect greater
reductions in the SOFA scores and indicate clinical improvement.
Figure 2.
Raw and Fitted Mortality Rates of Patients Treated With Saline Placebo or 6, 12, or 18 g of Levocarnitine Based on
the Modified Intent-to-Treat and Per-Protocol Analyses
Error bars represent SDs around raw and model-fitted mortality rates.
a
